Hematological Malignancies

Rituximab-Refractory Trial: Patient Response to Zevalin

Overall response rate

Estimated duration of response

8

P =0.002

P =0.002

0 10 20 30 40 50 60 70 80 90 100

6.5

6.4

6

74%

n =34

n =17

64%

n =54

4

n =54

n =51

4.4

n =17

2 Months

15% CR

Patients (%)

32%

0

Zevalin

Last Rituximab

Last Chemo- therapy

Zevalin

Last Rituximab

Last Chemo- therapy

Median TTP in responders 9.1 months (range: 3.5 to 25.9+ months)